Updated:
LAV Asset Management
Yi Shi founded LAV Asset Management in 2007 to invest exclusively in life sciences, backing biotechs like Zai Lab and Chi-Med from its Hong Kong-Shanghai base.
LAV Asset Management
LAV ASSET MANAGEMENT (HONG KONG) LIMITED is a SEC-registered investment adviser in Hong Kong, registered since 2023. It is based in Hong Kong.
General information
Firm type
Asset Manager
Year founded
2007
Location
Region
Asia
Country
Hong Kong
City
Hong Kong
Corporate office
Hong Kong, Hong Kong
Additional offices
Shanghai, China
Principals
Yi Shi
Founder and Managing Partner
James Zhi
Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at LAV?
Founder Yi Shi and Managing Partner James Zhi anchor the investment committee. Shi holds a PhD in biochemistry and brings a scientific lens to portfolio construction. The firm keeps its senior partner group small, with investment decisions made by the partnership rather than a single CIO.
Is LAV structured as a family office or does it operate more like a venture firm?
LAV operates as an institutional venture and growth equity manager raising third-party capital, not a family office. It manages USD and RMB-denominated funds from offices in Hong Kong and Shanghai, with limited partners including pension funds, sovereign wealth funds, and fund-of-funds.
What investment stages does LAV typically target?
LAV invests from early-stage venture through crossover and growth equity. The firm can hold positions from company formation through IPO and follow-on rounds. Its portfolio companies often list on Nasdaq or the Hong Kong Exchange, with LAV sometimes maintaining a position post-listing to capture commercial-stage growth.
Which sectors does LAV explicitly avoid?
LAV is exclusively life sciences and healthcare. The firm does not invest in consumer internet, enterprise software, fintech, or any non-healthcare verticals. Within healthcare, its portfolio spans biopharmaceuticals, medical devices, and diagnostics, but it does not pursue healthcare services or provider models outside of the innovation supply chain.
How does LAV source proprietary deal flow?
Academic spinouts and translational science labs form a critical sourcing channel, given the founding team's scientific credentials. LAV also relies on relationships with major pharmaceutical strategics who flag collaboration-ready assets. Its narrow mandate and hands-on board participation give the firm visibility into companies before they run broad auction processes.
Does LAV participate in fund commitments or only direct deals?
LAV deploys capital exclusively through direct equity investments in portfolio companies. The firm does not operate a fund-of-funds program, nor does it allocate to external managers as a core strategy. Its fund vehicles are direct-investment venture and growth equity pools.
What is LAV's known posture on co-investments alongside external GPs?
LAV syndicates with other life sciences specialists and generalist crossover funds on larger growth rounds. The firm does not publicly market a co-investment program, but its participation in consortium deals alongside global healthcare investors is a regular feature of later-stage rounds for its portfolio companies preparing for public listing.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on registered investment advisers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: